<DOC>
	<DOC>NCT01835197</DOC>
	<brief_summary>This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects.</brief_summary>
	<brief_title>First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Females must be of nonchild bearing potential and either at least 1 year post menopausal (FSH â‰¥40 IU/L), or have documented hysterectomy (with or without bilateral oophrectomy) at least 6 months prior to study day Subjects willing to defer receiving prophylactic immunizations (e.g. influenza or pneumococcal vaccines) during the study. Absolute lymphocyte count must be greater than or equal to the lower limit of the laboratory reference range. Subjects enrolled in Cohort 8 must have four Japanese grandparents born in Japan. Evidence or history of clinically significant hematological, renal, , pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). History of hepatitis or positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBc Ab) or hepatitis C antibodies (HCV). Clinically significant abnormality on chest Xray performed at screening or within 3 months of screening date; or history of tuberculosis or active or latent or inadequately treated infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Single- &amp; Multiple Dose Escalation</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>Pf-04965842</keyword>
</DOC>